Exploring Chemo-Free Immunotherapy and Challenges in Lymphoma Treatment

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 

1. Glofitamab for Relapsed/Refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36507690/

2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/31451445/

3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36548927/

4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:

https://pubmed.ncbi.nlm.nih.gov/35803286/

5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/35366963/

6. Epcoritamab + R2 in high-risk follicular lymphoma:

https://meetings.asco.org/abstracts-presentations/218265

7. Glofitamab in Mantle Cell Lymphoma:

https://ashpublications.org/blood/article/140/Supplement%201/178/489039